A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2017
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms ParvOryx02
- Sponsors Oryx GmbH & Co
- 07 Jun 2017 Biomarkers information updated
- 23 May 2017 According to an Oryx GmbH & Co media release, topline data from this trial expected in Q4 2017.
- 26 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.